The sell-off followed Ardelyx's August 6, 2026, earnings report, which revealed product revenue of $118.1 million and a loss of approximately $0.07 per share. These figures fell short of consensus estimates, prompting multiple analysts to slash their price targets. The company’s financial outlook also darkened as it lowered its full-year 2026 revenue guidance for IBSRELA to a range of $350 million to $370 million, down from its previous forecast of up to $430 million. Ardelyx is now reassessing the timeline for its long-term $1 billion revenue target for the drug.

In response to the market volatility, the law firm Levi & Korsinsky has initiated an investigation into potential securities law violations on behalf of shareholders. The firm is currently evaluating whether the company’s disclosures misled investors regarding its growth trajectory. Shareholders who incurred losses following the stock's slide to a $4.00 closing price on August 7 are being encouraged to submit brokerage records for a cost-free review of their potential recovery options.